Characteristics | Report no. | |||
---|---|---|---|---|
1 | 2 | 3 | 4 | |
Age (y) | 74 | 67 | 60 | 73 |
Breast cancer indicators | pT1cN0M0 | pT1cN0M0 | pT1bN0M0 | pT1cN0M0 |
Stage | IA | IA | IA | IA |
Surgery | Bp + SNLB | Bp + SNLB | Bp + SNLB | Bt + SNLB |
Histology | ILC | IDC | IDC | IDC |
Breast cancer subtype | ER + /PgR + /HER2− | ER−/PgR−/HER2 + | ER−/PgR−/HER2 + | ER + /PgR + /HER2− |
Adjuvant therapy for breast cancer | Radiotherapy followed by AI | Trastuzumab with R-DHAP | Trastuzumab | AI |
Lymphadenopathy in preoperative images | None | Axillary lymph node | None | None |
Lymphoma stage | I | IV | III | I |
Subtype | FL | MCL | FL | FL |
Therapy | None | R-CHOP then R-DHAP | R-CHOP | None |
Priority for PT | Breast cancer | MCL | FL | Breast cancer |
Year published | 2010 | 2016 | 2019 | 2022 |
References | [5] | [2] | [3] | Present study |